Skip to main content
. 2018 Oct 12;97(41):e12784. doi: 10.1097/MD.0000000000012784

Figure 3.

Figure 3

Measurements of disease control rates (DCRs) of capecitabine and temozolomide (CAPTEM) regimens to treat advanced neuroendocrine neoplasms (NENs). A, Forest plot; (B) sensitivity analysis; (C) subgroup analysis, and (D) funnel plot of single-proportion meta-analysis. CI = confidence interval.